amantadine / Generic mfg. - LARVOL DELTA

Impact of Propranolol and Amantadine Dual Therapy on Neurological Recovery in Adult Traumatic Brain Injury (ASHP 2025) - No abstract available

Clinical • CNS Disorders • Vascular Neurology

Utilization of Modafinil and Amantadine for Wakefulness in the Intensive Care Unit (ASHP 2025) - No abstract available

Critical care

Evaluation of Amantadine for Severe Traumatic Brain Injury (ASHP 2025) - No abstract available

CNS Disorders • Vascular Neurology

Repurposing Amantadine for Neuroprotection in Traumatic Brain Injury: Effects on Clinical Outcomes and Biomarker Profiles (ASHP 2025) - No abstract available

Biomarker • Clinical • Clinical data • CNS Disorders • Vascular Neurology

Recognizing Amantadine Induced Neurotoxicity in Renal Impairment (ASHP 2025) - No abstract available

Renal Disease

Use of Adjunctive Amantadine for Treatment of Pediatric Catatonia (ASHP 2025) - No abstract available

Clinical • Pediatrics

Modafinil and Amantadine for Wakefulness in the Intensive Care Unit (ASHP 2025) - "Hosted by the Section of Clinical Specialists and Scientists"

Critical care

Richardson Syndrome Variant of Progressive Supranuclear Palsy: A Case Report. (PubMed, Cureus) - "Initially, levodopa/benserazide was started at a dose of 500 mg/day and increased up to 1,000 mg/day. Amantadine at a dose of 200 mg/day and levodopa/carbidopa sustained release at a dose of 200/50 mg/day were added to the treatment regimen, but no effective clinical response was observed...This case highlights the subtle prodromal features and progressive course of PSP, emphasizing the importance of early recognition. It also contributes to the literature by illustrating the clinical progression and therapeutic challenges in managing PSP, underscoring the value of a multidisciplinary approach to optimize patient outcomes."

Journal • CNS Disorders • Progressive Supranuclear Palsy

Association between cognitive adverse effects of anticholinergic medication and development of dementia in Parkinson's disease. (PubMed, Parkinsonism Relat Disord) - "The cognitive adverse effects of anticholinergics were not associated with increased dementia risk. Prospective studies assessing individual variability in anticholinergic sensitivity and cognitive outcomes in PD are warranted."

Adverse events • Journal • Alzheimer's Disease • CNS Disorders • Dementia • Movement Disorders • Parkinson's Disease

Enhancing Identification Confidence in Non-Targeted Screening of Emerging Contaminants via an Ensemble Retention Time Prediction Model: Applications in Screening and Ecological Risk Assessment. (PubMed, Environ Pollut) - "Ecological risk assessment via toxicological priority index identified personal care products and pharmaceuticals as primarily high-risk ECs, with fipronil, ensulizole, lidocaine, amantadine, and sulpiride posing greatest risks. This ensemble framework provided precise RT prediction for NTS, improving EC detection efficiency and supporting risk management."

Journal

Effect on Dyskinesia of the Early Combination of Amantadine to Levodopa-Therapy in Parkinson's Disease: A Randomized, Placebo-Controlled Study (PREMANDYSK). (PubMed, Mov Disord) - P2 | "Adjunctive amantadine-IR in early PD halved dyskinesia incidence over 18 months. Long-lasting mechanisms could not be demonstrated and merit further investigation. Exploratory positive findings on the potential benefit of amantadine-IR on symptoms like freezing of gait and fatigue also call for further investigation."

Clinical • Journal • CNS Disorders • Fatigue • Movement Disorders • Parkinson's Disease

Bromocriptine, Selegiline and Amantadine in the Treatment of Depression-A Systematic Review. (PubMed, Pharmaceuticals (Basel)) - " Findings suggest that bromocriptine, amantadine, and selegiline may represent effective dopaminergic antidepressants, particularly for treatment-resistant or atypical depression. Further large-scale, methodologically rigorous studies are needed to confirm their clinical utility."

Journal • Review • CNS Disorders • Depression • Mood Disorders • Psychiatry

Enhancing amantadine delivery through PLGA micelles: a novel approach using oleic acid and Pluronic F68 for sustained release and reduced toxicity. (PubMed, RSC Adv) - "This formulation enables controlled release, potentially reducing administration frequency while extending therapeutic efficacy. The novelty of this study lies in the combination of Pluronic F68 and oleic acid surfactants, enhancing drug stability and delivery efficiency, making it a promising approach for improving amantadine delivery in Parkinson's treatment."

Journal • CNS Disorders • Movement Disorders

A spatiotemporal hypergraph self-attention neural networks framework for the identification and pharmacological efficacy assessment of Parkinson's disease motor symptoms. (PubMed, NPJ Parkinsons Dis) - "Based on this, we compared the behavioral differences in treatment effects between amantadine (AMAN) and clozapine (CLZ). Overall, our automated 3D behavioral analysis framework offers a high-throughput, objective, and precise approach to behavioral quantification, presenting a powerful tool for unraveling the mechanisms underlying LID and other movement disorders, as well as for advancing pharmacological research."

Journal • CNS Disorders • Movement Disorders • Parkinson's Disease

A meta-analysis of the long-term efficacy of Amantadine for Levodopa-induced dyskinesia in Parkinson's disease. (PubMed, Clin Park Relat Disord) - "Our findings suggest that Amantadine is an effective adjunct medication for improving LID and broader Parkinson's disease symptoms. However, evidence of its declining long-term efficacy and "adverseness" have important implications for its use in Parkinson's disease therapy."

Journal • Retrospective data • CNS Disorders • Movement Disorders • Parkinson's Disease

The efficacy and safety of low-intensity focused ultrasound pulses for prolonged disorders of consciousness: a study protocol for a randomized controlled trial. (PubMed, Front Neurol) - P=N/A | "Among them, only studies involving amantadine have provided Class II evidence...Chinese Clinical Trial Registry, ChiCTR2400092904. Registered on 26 November 2024."

Journal • CNS Disorders

Use of Symptomatic Drug Treatment for Fatigue in Multiple Sclerosis and Patterns of Work Loss. (PubMed, Ann Clin Transl Neurol) - "A potential minor treatment benefit is suggested by the statistically significant, small attenuation of worsening work loss following fatigue treatment initiation compared with untreated people with MS. No differences in treatment benefit were observed across fatigue treatments."

Journal • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Fatigue • Multiple Sclerosis • Psychiatry

Combined Cerebrolysin and Amantadine Sulfate Administration for Patients With Traumatic Brain Injury in the ICU (clinicaltrials.gov) - P3 | N=150 | Completed | Sponsor: Ain Shams University | Trial primary completion date: Mar 2025 ➔ May 2025 | Recruiting ➔ Completed

Trial completion • Trial primary completion date • CNS Disorders • Hematological Disorders • Vascular Neurology

Paratonia in dementia: diagnosis and management strategies. (PubMed, Neurodegener Dis Manag) - "Both patients demonstrated improvement in paratonia following amantadine treatment, with reduced stiffness and greater ease in caregiving tasks. The present case series highlights the role of amantadine in the management of paratonia and can contribute to the development of more treatment options."

Journal • Alzheimer's Disease • CNS Disorders • Dementia

QSAR design, syntheses, and in vitro assessment of bridged polycyclic alkyl aryl amines as uncompetitive nmda receptor antagonists for treatment of neurodegenerative disorders (Neuroscience 2025) - "To address this issue, uncompetitive NMDAR antagonism continues to be a worthwhile pursuit, as demonstrated by FDA approval of three compounds in that class - memantine for treatment of Alzheimer's Disease (AD), amantadine for treatment of Parkinson's Disease (PD), and the recent approval of Ketamine for treatment resistant major depressive disorder...Binding affinities at the NMDAR PCP site, measured via [³H]-MK-801 radioligand assays, ranged from 679 nM to 10,000 nM...Preliminary 2D QSAR model studies demonstrated strong predictive performance amongst the training and test set compound series (R² = 0.84, Q² = 0.76), while molecular docking was used to gain further insight into SAR relationships within the PCP binding site. These results establish bridged polycyclic alkyl aryl amine scaffolds as promising uncompetitive NMDAR antagonists and provide new insight into strategies for developing therapeutic agents targeting neurodegenerative disorders."

Late-breaking abstract • Preclinical • Alzheimer's Disease • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Movement Disorders • Parkinson's Disease • Psychiatry

Antinociceptive effect induced by amatadine in a model of Chronic Constriction Injury of the Rat's Infraorbital (Neuroscience 2025) - "Acute treatment with amantadine decreased nociceptive behaviors, decreased LP, and increased GSH concentrations in injured tissues 21 days post-injury, since nociceptive behaviors are already established. These findings lead us to assume that the development and maintenance of nociceptive behaviors is closely related to oxidative stress and that treatment with amantadine is able to modulate it."

Preclinical • CNS Disorders • Neuralgia

Acute Amantadine Enhances the Benefits of Delayed and Abbreviated Environmental Enrichment in a Pediatric Traumatic Brain Injury Model (Neuroscience 2025) - "EE, regardless of AMT or VEH treatment, and AMT in STD housing, improved motor and cognitive outcomes vs. STD + VEH (p<0.05). Additionally, AMT + EE outperformed VEH + EE in spatial learning and improved memory retention relative to AMT + STD (p<0.05)."

Clinical • CNS Disorders • Vascular Neurology • CA3

Striatal Neural Ensemble Codes for Normal, Parkinsonian, and Dyskinetic Movements (Neuroscience 2025) - "Levodopa (L-DOPA) and amantadine treatments both improved locomotion frequency but acted via distinct mechanisms...The results delineate two distinct therapeutic mechanisms, one that rebalances the activity of the direct and indirect pathways and another that selectively potentiates or depresses the activity of SPN populations encoding voluntary or involuntary actions. Overall, this study refines the understanding of striatal dysfunction in movement disorders, demonstrates that distinct neural populations underlie normal voluntary locomotion and involuntary dyskinetic movements, and defines two complementary routes for the development of symptomatic treatments."

CNS Disorders • Movement Disorders • Parkinson's Disease

Dual Approaches for Parkinson's Disease: Role of the Dopaminergic and Non-Dopaminergic Therapies. (PubMed, Curr Aging Sci) - "Non-dopaminergic approaches, such as MAO-B inhibitors, amantadine, anticholinergics, and deep brain stimulation, offer additional symptom control... This review underscores the importance of integrating traditional and emerging therapies for comprehensive PD management. Future research should focus on genetic insights, early detection, and innovative therapeutics to improve patient outcomes and quality of life."

IO biomarker • Journal • CNS Disorders • Gene Therapies • Movement Disorders • Parkinson's Disease

Bone Marrow Microenvironment-Responsive Nanomedicine Promotes Anti-Leukemia Activity In Vivo (ASH 2023) - "In addition, according to the natural “myeloid niche homing” characteristic of AML cells and the low-oxygen microenvironment in bone marrow, we constructed β-cyclodextrin azobenzene linker (AZO-β-CD)-modified fusion protein and amantadine-modified HSA protein (HSA-ADA), followed by the addition of anti-CD47... Thus, our findings reveal that nanomedicine could inhibit CD47-SIRPα signaling and contribute to anti-leukemia function effectively, which may be a new strategy for preventing and treating the recurrence of AML after transplantation."

IO biomarker • Preclinical • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Hematological Malignancies • Leukemia • Oncology • Transplantation • CD34 • HAVCR2 • SIRPA